After one or two vaccinations, subjects who were previously not affected by Zika showed antigen-specific antibody responses to the virus during initial testing in both low dose and
The phase 2 study, dubbed Hermione, evaluated MM-302, an antibody-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer patients who had earlier been treated with trastuzumab (Herceptin), pertuzumab (Perjeta)
Cabotegravir is yet to be approved by regulatory authorities anywhere in the world. It is the first injectable to be studied for efficacy in pre-exposure prophylaxis. Dubbed HPTN 083, the 4,500-subject
Under the deal, Bristol-Myers will pay $50m upfront and will be solely responsible for worldwide clinical development and commercialization activities associated to the NG-348 virus. The deal also
The study will investigate the effects of once-daily closed triple combination therapy fluticasone furoate/ umeclidinium/vilanterol compared to therapy with the once-daily dual combination therapy, Relvar/Breo(R) (FF/VI). Comprising three
The companies signed an exclusive option, collaboration and license agreement for the worldwide development and commercialization of Conatus’ emricasan, an investigational oral, pan-caspase inhibitor intended to treat non-alcoholic
The recommendation is for treating NSCLC patients whose tumors have high PD-L1 expression without any EGFR or ALK positive tumor mutations. The CHMP’s positive opinion came through from
The competition watchdog accused the company of breaking competition law by raising the price of hydrocortisone tablets from £0.70 to £88 over an eight-year span. Between 2008 and
Headquartered in Ahmedabad, India, Claris Injectables has a portfolio of essential generic injectable medicines like anesthesia and analgesics, renal, anti-infectives and critical care in a range of presentations
The deal includes refinancing of existing Capsugel debt of about $2bn. KKR acquired Capsugel from Pfizer for $2.4bn in 2011. Based in Morristown, New Jersey, Capsugel is engaged
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.